Researchers from U of T Medicine pinpoint issue that could be hampering common chemotherapy drug ➡️
Researchers at the University of Toronto’s Donnelly Centre for Cellular and Biomolecular Research have found two enzymes that work against the chemotherapy drug gemcitabine, preventing it from effectively treating pancreatic cancer.
The enzymes – APOBEC3C and APOBEC3D – increase during gemcitabine treatment and promote resistance to DNA replication stress in pancreatic cancer cells.
This, in turn, counteracts the effects of gemcitabine and allows for the growth of cancer cells.
Comments are closed.